This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

10 Alzheimer's Disease Treatment Stocks

Prana Biotechnology (PRAN)
Drug: PBT2
Drug type: Metal ions
Stage: Phase II
Prana has announced, but not yet started, a large phase IIb study of PBT2 in mild to moderate Alzheimer's patients to bolster an early signal of efficacy seen in a smaller phase IIa study.

AstraZeneca (AZN) and Targacept (TRGT)
Drug: AZD1446
Drug type: Nicotinic Acetylcholine Receptors
Stage: Phase II
A small (54 patient) phase II study of AZD1445 in combination with Aricept began in early 2010 with top-line data expected in late 2010 or early 2011.

Drug: RG3487
Drug type: Nicotinic Acetylcholine Receptors
Stage: Phase II
A phase II study combining RGB3487 with Aricept completed patient enrollment in the second quarter.

GlaxoSmithKline (GSK)
Drug: Affitope AD02
Drug type: Amyloid beta immunotherapy
Stage: Phase II
Results from a phase II study could be ready in 2012.

List compiled with assistance from BioMedTracker

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ELN $0.00 0.00%
BMY $67.85 -0.34%
BAX $37.68 -0.53%
JNJ $102.37 0.40%
LLY $83.65 -0.11%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs